docetaxel anhydrous has been researched along with Cystadenocarcinoma, Papillary in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Han, B; He, L; Li, Y; Yuan, J | 1 |
| Benjapibal, M; Edwards, CL; Kavanagh, JJ; Kudelka, AP; Vadhan-Raj, S; Valero, V; Vasuratna, A; Verschraegen, CF | 1 |
1 review(s) available for docetaxel anhydrous and Cystadenocarcinoma, Papillary
| Article | Year |
|---|---|
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemotherapy, Cancer, Regional Perfusion; Combined Modality Therapy; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Cytoreduction Surgical Procedures; Docetaxel; Female; Humans; Hyperthermia, Induced; Middle Aged; Neoplasm Grading; Peritoneal Neoplasms; Prognosis; Survival Rate; Taxoids; Thoracic Surgery, Video-Assisted | 2017 |
1 other study(ies) available for docetaxel anhydrous and Cystadenocarcinoma, Papillary
| Article | Year |
|---|---|
Docetaxel and cyclophosphamide induced remission in platinum and paclitaxel refractory ovarian cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carcinoma; Cyclophosphamide; Cystadenocarcinoma, Papillary; Docetaxel; Female; Humans; Middle Aged; Ovarian Neoplasms; Paclitaxel; Taxoids | 1998 |